Abstract
Parkinsons disease is a neurodegenerative movement disorder caused by a combination of environmental and genetic factors. Recent human genetic studies have identified five genes that are linked to Parkinsons disease (PD): α-synuclein, parkin, UCH-L1, DJ-1 and NR4A2. Among these genes, a variety of mutations in the human parkin locus have been found in many PD cases, both familial and sporadic. Parkin appears to be the most prevalent genetic factor in PD. It encodes for a protein-ubiquitin E3 ligase, whose loss-offunction mutations cause specific degeneration of dopamine (DA) neurons in substantia nigra in human patients. The accumulation of parkin substrates is thought to be the key factor in the selective death of DA neurons. Rapid progress in the identification of these substrates and the generation of genetic animal models has produced a plethora of knowledge about the biological function of parkin and its role in PD. These studies also offer novel pharmacological targets for the development of more selective therapeutic strategies. In this review, I will summarize results from this fast expanding field and discuss their potential implication in the treatment of Parkinsons disease.
Keywords: parkin, synuclein, parkinson's disease, ubiquitination, misfolding, microtubule, dopamine, tubulin
Current Neuropharmacology
Title: Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Volume: 1 Issue: 4
Author(s): Jian Feng
Affiliation:
Keywords: parkin, synuclein, parkinson's disease, ubiquitination, misfolding, microtubule, dopamine, tubulin
Abstract: Parkinsons disease is a neurodegenerative movement disorder caused by a combination of environmental and genetic factors. Recent human genetic studies have identified five genes that are linked to Parkinsons disease (PD): α-synuclein, parkin, UCH-L1, DJ-1 and NR4A2. Among these genes, a variety of mutations in the human parkin locus have been found in many PD cases, both familial and sporadic. Parkin appears to be the most prevalent genetic factor in PD. It encodes for a protein-ubiquitin E3 ligase, whose loss-offunction mutations cause specific degeneration of dopamine (DA) neurons in substantia nigra in human patients. The accumulation of parkin substrates is thought to be the key factor in the selective death of DA neurons. Rapid progress in the identification of these substrates and the generation of genetic animal models has produced a plethora of knowledge about the biological function of parkin and its role in PD. These studies also offer novel pharmacological targets for the development of more selective therapeutic strategies. In this review, I will summarize results from this fast expanding field and discuss their potential implication in the treatment of Parkinsons disease.
Export Options
About this article
Cite this article as:
Feng Jian, Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets, Current Neuropharmacology 2003; 1 (4) . https://dx.doi.org/10.2174/1570159033477053
DOI https://dx.doi.org/10.2174/1570159033477053 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Freezing Distortions and Photoluminescence Property in PbMoO<sub>4</sub> Micro- Octahedrons: An Experimental and Theoretical Study
Current Physical Chemistry Computational Modeling of Dielectrophoretic Microfluidic Channel for Simultaneous Separation of Red Blood Cells and Platelets
Current Signal Transduction Therapy SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry The Role of the Platelet Glycoprotein IIb / IIIa in Thrombosis and Haemostasis
Current Pharmaceutical Design Nanoparticles, Neurotoxicity and Neurodegenerative Diseases
Current Drug Metabolism The Malignant Obesity Hypoventilation Syndrome (MOHS)
Current Respiratory Medicine Reviews New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Are There Differences in Catecholamine Levels in Body Fluids of Individuals with and Without Sleep Bruxism? A Systematic Review
Current Chemical Biology Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine Lipid Rafts and Fas/CD95 Signaling in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Rheumatological Manifestations in Diabetes Mellitus
Current Diabetes Reviews Osteoarthritis: Is there a Window of Opportunity
Current Rheumatology Reviews Structural Biology of Recombinant Bovine Pancreatic Phospholipase A2 and its Inhibitor Complexes
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Recent Studies of Aldose Reductase Enzyme Inhibition for Diabetic Complications
Current Medicinal Chemistry Engineering of Nanoemulsions for Drug Delivery
Current Drug Delivery Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Mechanism-Based Probing, Characterization, and Inhibitor Design of Glycosidases and Glycosyltransferases
Current Topics in Medicinal Chemistry Dielectric Properties of Polymer Composites with Nanocarbon Allotropes
Current Applied Polymer Science